ENDRA Life Sciences NDRA
NASDAQ NDRA
$5.41 -0.03 (-0.64%)
As of: Aug 27, 2026 · 3:24 PM EDT

ENDRA Life Sciences (NDRA) Current Deferred Revenue (2024 - 2025)

ENDRA Life Sciences (NDRA) posted quarterly Current Deferred Revenue of $328610.0 for Q2 2025, down 15.9% quarter-over-quarter from $390722.0 in Q1 2025.

ENDRA Life Sciences (NDRA) Current Deferred Revenue (2024 - 2025) Analysis & Trends

ENDRA Life Sciences (NDRA) has reported Current Deferred Revenue for 2 consecutive years, with $328610.0 the latest figure, recorded in Q2 2025.

  • In Q2 2025, Current Deferred Revenue changed N/A year-over-year to $328610.0; the TTM figure through Jun 2025 stood at $328610.0 (changed N/A YoY), while the FY2024 annual figure was $799284.0, changed N/A from the prior year.
  • Current Deferred Revenue fell to $328610.0 in Q2 2025 per NDRA's latest filing, from $390722.0 in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $910556.0 in Q3 2024 and bottomed at $328610.0 in Q2 2025.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Thermo Fisher Scientific 234.15 Bn 230.09 Bn 8.34 Bn
2 Danaher 152.10 Bn 147.75 Bn 3.61 Bn
3 Natera 48.48 Bn 47.38 Bn 486.15 Mn
4 Agilent Technologies 44.35 Bn 42.55 Bn 990.00 Mn
5 Iqvia Holdings 43.68 Bn 41.60 Bn 1.44 Bn
6 Idexx Laboratories 43.02 Bn 42.83 Bn 779.09 Mn
7 Illumina 34.39 Bn 33.22 Bn 770.00 Mn
8 Mettler Toledo International 28.29 Bn 28.24 Bn 650.22 Mn
9 Labcorp Holdings 27.51 Bn 27.37 Bn 1.11 Bn
10 ENDRA Life Sciences 7.16 Mn 1.62 Mn -

Historic Data

Download Data
DateValue
Jun 30, 2025 328,610.00
Mar 31, 2025 390,722.00
Dec 31, 2024 799,284.00
Sep 30, 2024 910,556.00